Business Wire3h
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigin ...
FiercePharma5h
Vertex scores FDA nod for long-awaited non-opioid pain reliever Journavx
Vertex Pharmaceuticals has scored an FDA approval for Journavx (suzetrigine), a non-opioid ... despite the study meeting its primary endpoint. While safety is the key differentiator between Journavx ...
US FDA identifies cybersecurity risks in certain patient monitors
The U.S. Food and Drug Administration (FDA) said on Thursday it had identified three cybersecurity risks associated with ...
Becker's Hospital Review10h
FDA warns GLP-1 compounder over safety rules
The FDA issued a warning letter to ProRx, a compounding facility in Exton, Penn., after an inspection raised serious concerns regarding the safety and compliance of its drug products. The facility, ...